Relations between strain and gender dependencies of irinotecan toxicity and UGT1A1, CES2 and TOP1 expressions in mice

Toxicology Letters

Volumn 192, Issue 3, 2010, Pages 395-401

  Ahowesso, C ^a,b   Piccolo, E ^c   Li, X M ^a,b   Dulong, S ^a,b   Hossard, V ^a,b   La Sorda, R ^c   Filipski, E ^a,b   Tinari, N ^c   Delaunay, F ^d   Iacobelli, S ^c   Levi F ^a,b  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITY OF CHIETI   (Italy)

^d UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Cancer; Gender; Irinotecan; Personalized medicine; Phase II metabolism; Toxicity

Indexed keywords

CARBOXYLESTERASE; CARBOXYLESTERASE 2; DNA TOPOISOMERASE; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; LETHALITY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; STRAIN DIFFERENCE; TOXICITY TESTING; WEIGHT REDUCTION;

ANIMALS; CAMPTOTHECIN; CARBOXYLIC ESTER HYDROLASES; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION; GLUCURONOSYLTRANSFERASE; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, INBRED DBA; MICE, INBRED STRAINS; SEX FACTORS; SPECIES SPECIFICITY;

MUS;

EID: 75549090022     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2009.11.017     Document Type: Article

References (42)

1. Aschoff J. The phase-angle difference in circadian periodicity. In: Aschoff J. (Ed). Circadian Clocks (1965), North Holland Press, Amsterdam 262-278
2. Buckley D.B., and Klaassen C.D. Tissue- and gender-specific mRNA expression of UDP glucuronosyltransferases (UGTs) in mice. Drug Metab. Dispos. 35 (2007) 121-127
3. Buckley D.B., and Klaassen C.D. Mechanism of gender-divergent UDP-glucuronosyltransferase mRNA expression in mouse liver and kidney. Drug Metab. Dispos. 37 (2009) 834-840
4. Bur I.M., Cohen-Solal A.M., Carmignac D., Abecassis P.Y., Chauvet N., Martin A.O., van der Horst G.T., Robinson I.C., Maurel P., Mollard P., and Bonnefont X. The circadian clock components CRY1 and CRY2 are necessary to sustain sex dimorphism in mouse liver metabolism. J. Biol. Chem. 284 (2009) 9066-9073
5. Cecchin E., Corona G., Masier S., Biason P., Cattarossi G., Frustaci S., Buonadonna A., Colussi A., and Toffoli G. Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN-38 activation step in colorectal cancer patients. Clin. Cancer Res. 11 (2005) 6901-6907
6. Cecchin E., Innocenti F., D'Andrea M., Corona G., De Mattia E., Biason P., Buonadonna A., and Toffoli G. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J. Clin. Oncol. 27 (2009) 2457-2465
7. Charasson V., Bellott R., Meynard D., Longy M., Gorry P., and Robert J. Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin. Pharmacol. Ther. 76 (2004) 528-535
8. Chomczynski P., and Sacchi N. The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat. Protoc. 1 (2006) 581-585
9. Faratian D., Goltsov A., Lebedeva G., Sorokin A., Moodie S., Mullen P., Kay C., Langdon S., Goryanin I., and Harrison D.J. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res. 69 (2009) 13-20
10. Filipski E., Lemaigre G., Liu X.H., Méry-Mignard D., Mahjoubi M., and Lévi F. Circadian rhythm of irinotecan tolerability in mice. Chronobiol. Int. 21 (2004) 3-30
11. Fukuoka K., Adachi J., Nishio K., Arioka H., Kurokawa H., Fukumoto H., Ishida T., Nomoto T., Yokote H., Tomonari A., Narita N., Yokota J., and Saijo N. p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors. Jpn. J. Cancer Res. 88 (1997) 1009-1016
12. Granda T.G., D'Attino R.M., Filipski E., Vrignaud P., Garufi C., Terzoli E., Bissery M.C., and Lévi F. Circadian optimisation of irinotecan and oxaliplatin efficacy in mice. Br. J. Cancer 86 (2002) 999-1005
13. Gupta E., Lestingi T.M., Mick R., Ramirez J., Vokes E.E., and Ratain M.J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 54 (1994) 3723-3725
14. Innocenti F., and Ratain M.J. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. Oncology 17 (2003) 52-55
15. Huang R.S., and Ratain M.J. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J. Clin. 59 (2009) 42-55
16. Innocenti F., and Ratain M.J. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics 7 (2006) 1211-1221
17. Izukawa T., Nakajima M., Fujiwara R., Yamanaka H., Fukami T., Takamiya M., Aoki Y., Ikushiro S., Sakaki T., and Yokoi T. Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. Drug Metab. Dispos. 37 (2009) 1759-1768
18. de Jong F.A., Scott-Horton T.J., Kroetz D.L., McLeod H.L., Friberg L.E., Mathijssen R.H., Verweij J., Marsh S., and Sparreboom A. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin. Pharmacol. Ther. 81 (2007) 42-49
19. Kaniwa N., Kurose K., Jinno H., Tanaka-Kagawa T., Saito Y., Saeki M., Sawada J.I., Tohkin M., and Hasegawa R. Racial variability in haplotype frequencies of ugt1a1 and glucuronidation activity of a novel single nucleotide polymorphism 686C > T (P229L) found in an African-American. Drug Metab. Dispos. 33 (2005) 458-465
20. Kawato Y., Aonuma M., Hirota Y., Kuga H., and Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 51 (1991) 4187-4191
21. Krishnaswamy S., Hao Q., Al-Rohaimi A., Hesse L.M., von Moltke L.L., Greenblatt D.J., and Court M.H. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics. I. Identification of polymorphisms in the 5′-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation. J. Pharmacol. Exp. Ther. 313 (2005) 1331-1339
22. Kweekel D., Guchelaar H.J., and Gelderblom H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev. 34 (2008) 656-669
23. Lamba J.K., Lin Y.S., Schuetz E.G., and Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 54 (2002) 1271-1294
24. Lankisch T.O., Schulz C., Zwingers T., Erichsen T.J., Manns M.P., Heinemann V., and Strassburg C.P. Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol. Biomarkers Prev. 17 (2008) 695-701
25. Lévesque E., Girard H., Journault K., Lépine J., and Guillemette C. Regulation of the UGT1A1 bilirubin-conjugating pathway: role of a new splicing event at the UGT1A locus. Hepatology 45 (2007) 128-138
26. Lévi F., and Schibler U. Circadian rhythms: mechanisms and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 593-628
27. Lévi F., Okyar A., Dulong S., Innominato P.F., and Clairambault J. Circadian Timing in Cancer Treatments. Annu. Rev. Pharmacol. Toxicol. 50 (2010) 375-419
28. Luquita M.G., Catania V.A., Pozzi E.J., Veggi L.M., Hoffman T., Pellegrino J.M., Ikushiro S., Emi Y., Iyanagi T., Vore M., and Mottino A.D. Molecular basis of perinatal changes in UDP-glucuronosyltransferase activity in maternal rat liver. J. Pharmacol. Exp. Ther. 298 (2001) 49-56
29. Marcuello E., Altes A., Menoyo A., Del Rio E., and Gomez-Pardo M.B. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 91 (2004) 678-682
30. Moisan F., Longy M., Robert J., and Le Morvan V. Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell lines. Br. J. Cancer. 95 (2006) 906-913
31. Ohdo S., Makinosumi T., Ishizaki T., Yukawa E., Higuchi S., Nakano S., and Ogawa N. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice. J. Pharmacol. Exp. Ther. 283 (1997) 1383-1388
32. Rosner G.L., Panetta J.C., Innocenti F., and Ratain M.J. Pharmacogenetic pathway analysis of irinotecan. Clin. Pharmacol. Ther. 84 (2008) 393-402
33. Rouits E., Charasson V., Pétain A., Boisdron-Celle M., Delord J.P., Fonck M., Laurand A., Poirier A.L., Morel A., Chatelut E., Robert J., and Gamelin E. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br. J. Cancer 99 (2008) 1239-1245
34. van Schaik R.H. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist. Updat. 11 (2008) 77-98
35. Stern S.T., Tallman M.N., Miles K.K., Ritter J.K., and Smith P.C. Androgen regulation of renal uridine diphosphoglucuronosyltransferase 1A1 in rats. Drug Metab. Dispos. 36 (2008) 1737-1739
36. Sugimoto Y., Tsukahara S., Oh-Hara T., Isoe T., and Tsuruo T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res. 50 (1990) 6925-6930
37. Takatani H., Oka M., Fukuda M., Narasaki F., Nakano R., Ikeda K., Terashi K., Kinoshita A., Soda H., Kanda T., Schneider E., and Kohno S. Gene mutation analysis and quantitation of DNA topoisomerase I in previously untreated non-small cell lung carcinomas. Jpn. J. Cancer Res. 88 (1997) 160-165
38. Taniguchi K., Kohno K., Kawanami K., Wada M., Kanematsu T., and Kuwano M. Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins. Cancer Res. 56 (1996) 2348-2354
39. Tampellini M., Filipski E., Liu X.H., Lemaigre G., Li X.M., Vrignaud P., François E., Bissery M.C., and Lévi F. Docetaxel chronopharmacology in mice. Cancer Res. 58 (1998) 3896-3904
40. Wasserman E., Myara A., Lokiec F., Goldwasser F., Trivin F., Mahjoubi M., Misset J.L., and Cvitkovic E. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann. Oncol. 8 (1997) 1049-1051
41. Wolkenhauer, O., Auffray, C., Baltrusch, S., Blüthgen, N., Byrne, H., Cascante, M., Ciliberto, A., Dale, T., Drasdo, D., Fell, D., Ferrell, J., Gallahan, D., Gatenby, R., Guenther, U., Herzel, H., Junghanss, C., Kunz, M., Laplace, F., van Leeuwen, I., Lenormand, P., Lévi, F., Linnebacher, M., Lowengrub, J., Maini, P.K., Marcus, F., Malik, A., Rateitschak, K., Sansom, O., Schäfer, R., Schürrle, K., Sers, C., Schnell, S., Harms, B., Shibata, D., Tyson, J., Vera, J., White, M., Zhivotovsky, B., Jaster, R., in press. Systems biologists hope for a full integration of their field into cancer research. Cancer Res.
42. Xu G., Zhang W., Ma M.K., and McLeod H.L. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin. Cancer Res. 8 (2002) 2605-2611